Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): An open-label, randomised, phase 3 factorial trial

The Lancet Oncology

Volumn 15, Issue 10, 2014, Pages 1076-1089

  Denham, James W ^a   Joseph, David ^b   Lamb, David S ^c   Spry, Nigel A ^b   Duchesne, Gillian ^d   Matthews, John ^e   Atkinson, Chris ^f   Tai, Keen Hun ^e   Christie, David ^g   Kenny, Lizbeth ^h   Turner, Sandra ⁱ   Gogna, Nirdosh Kumar ^j   Diamond, Terry ^a,j   Delahunt, Brett ^b,k   Oldmeadow, Christopher ^a,c,l   Attia, John ^a,m   Steigler, Allison ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c WELLINGTON HOSPITAL   (New Zealand)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f St Georges Cancer Care Centre   (New Zealand)

^g Genesiscare   (Australia)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁱ WESTMEAD HOSPITAL   (Australia)

^j PRINCESS ALEXANDRA HOSPITAL   (Australia)

^k ST GEORGE HOSPITAL   (Australia)

^l UNIVERSITY OF OTAGO   (New Zealand)

^m HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; AUSTRALIA; BONE METASTASIS; BRACHYTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; FAINTNESS; FEVER; FOLLOW UP; GLEASON SCORE; HEART INFARCTION; HEMATURIA; HEMIPARESIS; HUMAN; HYPOTENSION; INCIDENCE; INJECTION SITE ABSCESS; INTERMEDIATE TERM ANDROGEN SUPPRESSION THERAPY; JAW OSTEONECROSIS; KIDNEY PAIN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; NEW ZEALAND; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SHORT TERM ANDROGEN SUPPRESSION THERAPY; THORAX PAIN; TREATMENT DURATION; URINARY TRACT OBSTRUCTION; URINE RETENTION; URTICARIA; ADENOCARCINOMA; BLOOD; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84908567692     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70328-6     Document Type: Article

References (42)

1. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 50:1243-1252.
2. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005, 6:841-850.
3. Bolla M, De Reijke TM, van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
4. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
5. Freedland SJ, Eastham J, Shore N Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2009, 12:333-338.
6. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011, 12:451-459.
7. Neville-Webbe HL, Holen I, Coleman RE The anti-tumour activity of bisphosphonates. Cancer Treat Rev 2002, 28:305-319.
8. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
9. Denham JW, Wilcox C, Lamb DS, et al. Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiother Oncol 2012, 105:184-192.
10. Denham JW, Wilcox C, Joseph D, et al. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol 2012, 13:1260-1270.
11. Denham JW, Nowitz M, Joseph D, et al. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer. BJU Int 2014, published online Feb 11. 10.1111/bju.12497.
12. Denham JW, Steigler A, Wilcox C, et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol 2008, 9:1058-1068. on behalf of the Trans-Tasman Radiation Oncology Group 96.01 Trialists.
13. Denham JW, Steigler A, Wilcox C, et al. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?. Cancer 2009, 115:4477-4487.
14. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
15. Haworth A, Kearvell R, Greer PB, et al. Assuring high quality treatment delivery in clinical trials: results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study. Radiother Oncol 2009, 90:299-306.
16. Ebert MA, Haworth A, Kearvell R, et al. Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system. Radiother Oncol 2008, 86:200-210.
17. Harrison KM, Ebert MA, Kron T, et al. Design, manufacture, and evaluation of an anthropomorphic pelvic phantom purpose-built for radiotherapy dosimetric intercomparison. Med Phys 2011, 38:5330-5337.
18. Ebert MA, Harrison KM, Howlett SJ, et al. Dosimetric intercomparison for multicentre clinical trials using a patient-based anatomic pelvic phantom. Med Phys 2011, 38:5167-5175.
19. Roach M, Lu J, Pilepich MV, et al. Predicting long-term survival and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000, 47:617-627.
20. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007, 18:805-835.
21. Knol MJ, VanderWeele TJ Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol 2012, 41:514-520.
22. Gail M, Simon R Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985, 41:361-372.
23. Fine JP, Gray RJ A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
24. Wirth M, Tammela T, Cicalese V, et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol 2014, published online Feb 20. 10.1016/j.eururo.2014.02.014.
25. Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance). J Clin Oncol 2014, published online March 3. 10.1200/JCO.2013.51.6500.
26. Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003, 95:1300-1311.
27. Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer: results of a randomized double-blind placebo-controlled trial-Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007, 99:765-776.
28. Roato I Interaction among cells of bone, immune system, and solid tumors leads to bone metastases. Clin Dev Immunol 2013, 2013:315024.
29. Brennen WN, Chen S, Denmeade SR, Isaacs JT Quantification of mesenchymal stem cells (MSCs) at sites of human prostate cancer. Oncotarget 2013, 4:106-117.
30. Pedersen EA, Shiozawa Y, Pienta KJ, Taichman RS The prostate cancer bone marrow niche: more than just 'fertile soil'. Asian J Androl 2012, 14:423-427.
31. Park SI, Soki FN, McCauley LK Roles of bone marrow cells in skeletal metastases: no longer bystanders. Cancer Microenviron 2011, 4:237-246.
32. Thulin MH, Jennbacken K, Damber JE, Welen K Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies. Clin Exp Metastasis 2014, 31:269-283.
33. Sieh S, Taubenberger AV, Lehman M, Clements JA, Nelson CC, Hutmacher DW Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis. Bone 2014, 63:121-131.
34. Kim JK, Jung Y, Wang J, et al. TBK1 regulates prostate cancer dormancy through mTOR inhibition. Neoplasia 2013, 15:1064-1074.
35. Koch FP, Merkel C, Al-Nawas B, et al. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner: a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. J Craniomaxillofac Surg 2011, 39:562-569.
36. Ebert R, Zeck S, Krug R, et al. Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 2009, 44:858-864.
37. Denham JW, Steigler A, Tai KH, et al. Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. Radiother Oncol 2013, 107:123-128.
38. Todenhofer T, Hennenlotter J, Kuhs U, et al. Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?. World J Urol 2013, 31:345-350.
39. Nabid A, Carrier N, Martin A-G, et al. High risk prostate cancer treated with pelvic radiotherapy and 36 vs 18 months of androgen blockade: results of a phase III randomized trial. 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium; Orlando, FL, USA; Feb 14-16, 2013. Proc Am Soc Clin Oncol 2013, 31(suppl 6). abstr 3.
40. Sydes MR, Parmar MK, James ND, et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009, 10:39.
41. Shahinian VB Reducing fracture risk in men on androgen deprivation therapy. Nat Rev Urol 2011, 8:9-10.
42. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038-1042.